Core Facility for Abeta Microdialysis Drug Discovery Platform

Funding year(s): 
2007 - 2009
Funding to date: 
$278,238

In collaboration with an anonymous funder, Cure Alzheimer’s Fund is supporting development of a facility to measure the concentration of Amyloid-beta in real time in the brain of living, behaving mouse models that develop features of AD. The model enables screening for drugs that lower Amyloid-beta directly in the brain in relatively high throughput.

Researchers

Headshot photo
David Michael Holtzman, MD

The Andrew B. and Gretchen P. Jones Professor of Neurology and head of the Department of Neurology, Washington University, St. Louis
Charlotte and Paul Hagemann Professor of Neurology and Molecular Biology and Pharmacology
Associate Director of the Alzheimer's Disease Research Center
Member of the Hope Center for Neurological Disorders